Midterm outcomes of patellofemoral matrix associated chondrocyte implantation - are they as good as femoral condyle outcomes?
ESSKA Academy. Matthews E. 11/08/19; 284387; epEKA-55 Topic: Sports Related Injuries
Mr. Edward Matthews
Mr. Edward Matthews
Login now to access Regular content available to all registered users.

You can access free regular educational content on the ESSKA Academy by registering as an 'ESSKA Academy User’ here

Access to Premium content is currently a membership benefit.

Click here to join ESSKA or renew your membership.
Abstract
Discussion Forum (0)
Rate & Comment (0)
Midterm outcomes of patellofemoral matrix associated chondrocyte implantation - are they as good as femoral condyle outcomes?

ePoster - epEKA-55

Topic: HTO

Matthews E., Walmsley K., Schranz P., Mandalia V.
Exeter Knee Reconstruction Unit, Exeter, United Kingdom

Background: The treatment of cartilage defects in young patients is challenging and patellofemoral lesions have been suggested as more difficult to treat. The technology and indication for surgery is evolving and with the aim to regenerate the cartilage based tissue and improve symptoms.
Aim: To report the mid-term clinical results and patient related outcome measures of NOVOCART-3D Matrix Associated Chondrocyte Implantation (MACI) of the patellofemoral joint (PFJ) in comparison to the tibiofemoral joint (TFJ).
Methods: Prospective evaluation of 46 patients, 17 of which who underwent MACI between 2011 and 2017 their PFJ. Outcome measures used were KOOS, reoperation and complications.
Results: Forty-six patients were evaluated. Mean follow up period of 28.8 months (range 6-84).
Mean age 33 years (range 16-56)
· 29 were male and 17 female
The mean cartilage defect was 4.1cm2 (range 1.2-10.5).
The KOOS scores of patients with patellofemoral defects improved more than tibiofemoral in all subscales apart from QoL.
Patients demonstrated improvements in all KOOS sub scores:
· Patellofemoral scores improved more than tibiofemoral lesions in pain, symptoms and ADL subscores
· QoL subscore had the largest rise amongst subscores
All but two patients were satisfied and would undergo surgery again. 28 patients (60%) returned to pre-injury activity levels.
Six (13%) patients underwent further surgery for pathology related to the MACI graft; three further patients had surgery elsewhere in the knee.
One patient died of an unrelated illness; one suffered a pulmonary embolus and one a superficial infection.
Conclusion:
· PFJ lesions respond well to surgery and resulted in few complications or return to surgery
· Statistically significant improvement in PFJ KOOS outcomes in pain, symptoms and ADL over TFJ lesions
· Our MACI outcomes demonstrate improvements in all sub-scales of the KOOS values at midterm follow up.
Midterm outcomes of patellofemoral matrix associated chondrocyte implantation - are they as good as femoral condyle outcomes?

ePoster - epEKA-55

Topic: HTO

Matthews E., Walmsley K., Schranz P., Mandalia V.
Exeter Knee Reconstruction Unit, Exeter, United Kingdom

Background: The treatment of cartilage defects in young patients is challenging and patellofemoral lesions have been suggested as more difficult to treat. The technology and indication for surgery is evolving and with the aim to regenerate the cartilage based tissue and improve symptoms.
Aim: To report the mid-term clinical results and patient related outcome measures of NOVOCART-3D Matrix Associated Chondrocyte Implantation (MACI) of the patellofemoral joint (PFJ) in comparison to the tibiofemoral joint (TFJ).
Methods: Prospective evaluation of 46 patients, 17 of which who underwent MACI between 2011 and 2017 their PFJ. Outcome measures used were KOOS, reoperation and complications.
Results: Forty-six patients were evaluated. Mean follow up period of 28.8 months (range 6-84).
Mean age 33 years (range 16-56)
· 29 were male and 17 female
The mean cartilage defect was 4.1cm2 (range 1.2-10.5).
The KOOS scores of patients with patellofemoral defects improved more than tibiofemoral in all subscales apart from QoL.
Patients demonstrated improvements in all KOOS sub scores:
· Patellofemoral scores improved more than tibiofemoral lesions in pain, symptoms and ADL subscores
· QoL subscore had the largest rise amongst subscores
All but two patients were satisfied and would undergo surgery again. 28 patients (60%) returned to pre-injury activity levels.
Six (13%) patients underwent further surgery for pathology related to the MACI graft; three further patients had surgery elsewhere in the knee.
One patient died of an unrelated illness; one suffered a pulmonary embolus and one a superficial infection.
Conclusion:
· PFJ lesions respond well to surgery and resulted in few complications or return to surgery
· Statistically significant improvement in PFJ KOOS outcomes in pain, symptoms and ADL over TFJ lesions
· Our MACI outcomes demonstrate improvements in all sub-scales of the KOOS values at midterm follow up.
Code of conduct/disclaimer available in General Terms & Conditions

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies